Company: JUNS
Filing Date: 2025-05-15
Form Type: 10-Q
Source: 0001641172-25-010990
Chunk: 63

Company: JUPITER NEUROSCIENCES, INC.
Filing Date: 2025-05-15
Form: 10-Q
Item: Item 2
Chunk 63
---
 of 2,750,000 shares of our common stock, par value $0.0001 per share (“common stock”) at
a price of $4.00 per share. In connection with the Public Offering, the Company’s common stock was registered under Section
12(b) of the Exchange Act and began trading on The Nasdaq Capital Market under the symbol “JUNS.”

Business Overview

The Company’s platform product, JOTROL,
is an enhanced orally administered resveratrol formulation designed and intended to deliver therapeutically relevant, safe levels of resveratrol.
This platform has many potential indications of use for rare diseases, which include Mucopolysaccharidoses Type 1, Friedreich’s
ataxia and MELAS. In the larger disease areas, we are primarily targeting Parkinson’s Disease and Mild Cognitive Impairment/early
Alzheimer’s disease.

The present primary target for the Company is
treatment of Parkinson’s Disease (PD). The Company completed preclinical activities in a validated mouse model of Parkinson’s
Disease (PD) at the University of Miami in 2021. The model of Parkinson’s Disease that was
used in this preclinical study mimics many aspects of the disease utilizing a unilateral injection of a neurotoxin precursor that elicits
nigral cell loss, striatal dopamine loss and behavior deficits similar to physiological characteristics of human disease.

We believe that
results from this preclinical study indicate that Parkinson’s Disease might be the best target for treatment and financial opportunity
among the multiple indications where JOTROL might play a role. The Company is now in the process of planning its first Phase II clinical
trial in a patient population. This will be a Phase IIa study conducted with the assistance of Zina Biopharmaceuticals that is led by
Dr. Charbel Moussa, MBBS,Ph.D. The study is expected to start in the third quarter of 2025 and have results available approximately 12
months thereafter.

We are also targeting the treatment of MCI/early
Alzheimer’s Disease. We received funding of $2.2 million from the National Institute of Aging (“NIA”) in in 2020 and
2022 from a grant application for a Phase 1 study for Mild Cognitive Impairment/ Alzheimer. In the NIA scientific review summary
statement of our Phase I study application, it is stated that the NIA is looking forward to a Phase II study with an enhanced resverat